Fraud suit against Novartis, GSK wrapping up; Equity firms reconsider Indian deals

> Attorneys are set to begin closing arguments in the trial of the state of Alabama's Medicaid fraud lawsuit against Novartis and GlaxoSmithKline. Report

> In the wake of the recent Ranbaxy-Daiichi deal, private equity firms are treading a more cautious path in their approach towards investments in the fast-growing Indian drug companies. Report

> Galapagos said its service division BioFocus DPI will provide compound management and related services to Sepracor for about $1.5 million over three years. Report

> Watson Pharmaceuticals launched an authorized generic of Solvay Pharmaceuticals' nausea treatment Marinol. Report

> Dermatology specialist Stiefel Laboratories' buyout of a New Jersey-based competitor promises to increase its product portfolio and hike its Atlanta-area workforce by about 10 percent. Report

> New Hampshire Attorney General Kelly Ayotte is pushing for a central database to track commonly abused prescription drugs such as stimulants, painkillers and muscle relaxants. Report

> There's more bad news for the U.K.'s drug development industry. Pfizer, Roche and Merck Serono have all decided to cut back on clinical research there, according to the Financial Times. Report

> Life science supplier Millipore is giving a $3.4 million boost to its St. Charles, Missouri facility, which is the headquarters for its drug discovery business unit. Report

> GlaxoSmithKline is ending its six-year-long collaboration with Exelixis in October. Report

> Canada's biotech sector is growing, but the country is struggling to find enough "job-ready" candidates. Canada report

And Finally... Think you make your own choices? Think again, new brain research shows. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.